HCW Biologics Inc. (HCWB) a clinical-stage biopharmaceutical company, Monday said that the Food and Drug Administration (FDA)has ...

HCW Biologics (HCWB) announced that it has received clearance of its Investigational New Drug Application, IND, from the U.S. Food and Drug ...

This study will evaluate HCW9302 in patients with moderate to severe alopecia areataMIRAMAR, Fla., Feb. 03, 2025 (GLOBE ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update Gearing Up to Initiate Phase 3 Ovarian Cancer Trial Imunon, Inc. (NASDAQ:IMNN) is continuing preparations to conduct a Phase 3 clinical trial of ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

Medically reviewed by Femi Aremu, PharmD Inflammation is a normal part of the body's immune response to pain, injury, or infections. Acute (short-term) inflammation helps heal the body and protect ...

Serum soluble interleukin-2 receptor (sIL-2R) levels have been a great diagnostic tool for non-Hodgkin lymphoma (NHL) and ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Coherus markets LOQTORZI® (toripalimab-tpzi), a novel next-generation PD-1 inhibitor, and UDENYCA® (pegfilgrastim-cbqv), a biosimilar of Neulasta. In December 2024, Coherus announced the planned ...

After many months, if not years, of leaks and speculation, it’s finally official: Nintendo has announced its next console, and it’s called Nintendo Switch 2. As the name implies, it’s a very ...